The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of mFOLFOX with bevacizumab (Bev) in metastatic gastroesophageal and gastric (GE) adenocarcinoma (AC).
Jia Li
No relevant relationships to disclose
Jeremy S. Kortmansky
No relevant relationships to disclose
Neal A. Fischbach
No relevant relationships to disclose
Stacey Stein
No relevant relationships to disclose
Xiaopan Yao
No relevant relationships to disclose
Howard S. Hochster
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Jill Lacy
No relevant relationships to disclose